A randomized, placebo-controlled phase Ib/IIa trial to evaluate the safety, tolerability, and efficacy of BGT-002, an adenosine triphosphate citrate lyase inhibitor in patients with NAFLD: interim analysis

BGT-002 - Burgeon Therap

Yue Hu1; Hong Zhang1; Guoyue LV1; Fajun Nan2; Jingya LI2; Yangming Zhang2; Dandan Wu1; Yanhua Ding3; Junqi Niu1

Apr 2, 2024